NANOG and hyperlipidemia: Building upon these benchmark data, we sought to explore the impact of prolonged hyperlipidemia as well as the effect colchicine-based therapy on a variety of atheroprotective (Klotho, HOXA5, NOTCH1, and OCT4) and proatherogenic (HIF1a, SOX2, BMP4, and NANOG) genes.